The Study of Pharmacokinetic Interactions Between HL237 and Tacrolimus

Exclusion Criteria

• •Subject with serious cardiovascular, respiratory, hepatology, renal, hematologic, gastrointestinal, immunologic, dermal, neurologic, or psychological disease or history of such disease
• •Subject with symptoms of acute disease within 28 days prior to investigational products dosing
• •Subject with medical history which able to affect absorption, distribution, metabolism and excretion of drug
• •Subject with hypersensitive reaction to following drug or history of clinically significant hypersensitive reaction to following drug
• •* Calcineurin inhibitor or Macrolides
• •* HL237
• •Subject with clinically significant active chronic disease
• •Subject with genetic deficiency such as galactose intolerance, Lapp lactose deficiency or glucosegalactose malabsorption
• •Subjects who showed one or more of the following in a screening test including a retest
• •* AST, ALT \> UNL (upper normal limit) x 2.5
• •* Creatinine clearance =\< 80mL/min (Cockcroft-Gault GFR = (140-age) \* (Wt in kg) / (72 \* Cr))
• •* Results of ECG, QTc \> 450 msec
• •Positive test results for hepatitis B virus surface antigen, anti-hepatitis C virus antibody, anti-Human Immunodeficiency virus antibody or venereal disease research laboratory test
• •Use of any prescription medication within 14 days prior to study medication dosing
• •Use of any over-the-counter(OTC) medication within 7 days prior to study medication dosing
• •Subject with clinically significant allergic disease (except for mild allergic rhinitis and mild allergic dermatitis that are not needed to administer drug)
• •Subject who is not able to taking standard meals provided by the institution
• •Subject with whole blood donation within 60 days, component blood donation within 20 days
• •Subjects receiving blood transfusion within 30 days prior to study medication dosing
• •Participation in any clinical investigation within 6 months prior to study medication dosing
• •Use of any medication effected on drug enzyme induction or inhibition such as barbitals within 30 days prior to study medication dosing
• •Subjects who have continuously consumed grapefruit juice or caffeine (grapefruit juice or caffeine \> 5 cups/day), or who can't refrain from intake during hospitalization
• •Subjects who have continued to drink alcohol (alcohol\> 30 g/day) or who can't quit drinking during hospitalization
• •Severe heavy smoker(cigarette \> 10 cigarettes per day) or subjects who can't quit smoking during hospitalization
• •Subjects that the investigator deems unsuitable for participation in the clinical trial due to laboratory test results or other excuse such as non-responding to request or instruction by investigator